TB/Flu-06E
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating…
Read MorerAd-Rv2299c
rAd-Rv2299c is a chimpanzee adenovirus-vectored vaccine expressing Rv2299c. Constructed using pRSK17 shuttle plasmid, packaged in HEK293A cells, and purified by cesium chloride density centrifugation. Formulated for intranasal inhalation at 1×10⁸ PFU/50 μL PBS. The platform exhibits low human seroprevalence with trained immunity induction in DCs. No exogenous adjuvants.
Read MoreAd5-105K
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb). The adenovirus type 5 (Ad5) backbone functions as…
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreTri:ChAd:TB
Tri:ChAd:TB is built on the chimpanzee adenovirus serotype 68 vector, expressing Ag85A, TB10.4, and RpfB. These antigens spanning distinct M.tb life-cycle stages. Ag85A wanes after acute infection, whereas TB10.4 remains highly expressed. RpfB is upregulated during dormancy and resuscitation. This vaccine is formulated for respiratory mucosal delivery.
Read More